Media coverage about Esperion Therapeutics (NASDAQ:ESPR) has trended somewhat positive this week, according to Accern Sentiment. The research group ranks the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Esperion Therapeutics earned a news impact score of 0.09 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 46.9254333827209 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the media headlines that may have impacted Accern Sentiment’s rankings:
- Esperion Therapeutics (ESPR) Given Consensus Rating of “Buy” by Brokerages (americanbankingnews.com)
- Esperion Therapeutics (ESPR) Given a $64.00 Price Target at Deutsche Bank (americanbankingnews.com)
- Esperion Therapeutics (ESPR) Receives “Buy” Rating from Stifel Nicolaus (americanbankingnews.com)
- Esperion Therapeutics, Inc. (ESPR) EPS Estimated At $-1.45 (nmsuherald.com)
- Hot Stock of the Day – Esperion Therapeutics, (NASDAQ: ESPR) (stocksnewstimes.com)
Several research analysts have weighed in on the stock. UBS set a $90.00 price target on shares of Esperion Therapeutics and gave the company a “neutral” rating in a report on Wednesday, February 21st. JPMorgan Chase reissued a “neutral” rating and issued a $65.00 price target (up from $55.00) on shares of Esperion Therapeutics in a report on Wednesday, February 21st. BidaskClub raised shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, December 16th. ValuEngine raised shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Finally, Stifel Nicolaus set a $105.00 price target on shares of Esperion Therapeutics and gave the company a “buy” rating in a report on Wednesday, March 7th. Six investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $92.54.
Esperion Therapeutics (NASDAQ:ESPR) last announced its earnings results on Tuesday, February 20th. The biopharmaceutical company reported ($1.44) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.80) by $0.36. During the same quarter last year, the business posted ($1.29) EPS. sell-side analysts expect that Esperion Therapeutics will post -5.61 earnings per share for the current year.
In other Esperion Therapeutics news, Director Nicole Vitullo sold 11,674 shares of the stock in a transaction that occurred on Thursday, January 25th. The shares were sold at an average price of $71.79, for a total transaction of $838,076.46. Following the transaction, the director now owns 3,177 shares in the company, valued at approximately $228,076.83. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Roger S. Newton sold 25,000 shares of the stock in a transaction that occurred on Thursday, March 29th. The stock was sold at an average price of $72.37, for a total transaction of $1,809,250.00. Following the transaction, the director now owns 639,682 shares in the company, valued at approximately $46,293,786.34. The disclosure for this sale can be found here. Corporate insiders own 32.50% of the company’s stock.
About Esperion Therapeutics
Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.